Comparative Pharmacology
Head-to-head clinical analysis: DOLOBID versus OXYPHENBUTAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLOBID versus OXYPHENBUTAZONE.
DOLOBID vs OXYPHENBUTAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
250-500 mg orally twice daily. Maximum 1500 mg/day.
100-200 mg orally 3-4 times daily, not to exceed 600 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (dose-dependent; prolonged up to 15 hours with higher doses). Clinical context: allows twice-daily dosing; extended half-life in renal impairment.
Clinical Note
moderateOxyphenbutazone + Gatifloxacin
"Oxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxyphenbutazone + Rosoxacin
"Oxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxyphenbutazone + Levofloxacin
"Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxyphenbutazone + Trovafloxacin
Terminal elimination half-life ranges from 27 to 64 hours (mean ~50 hours). Prolonged in hepatic or renal impairment; may extend up to 100 hours in elderly.
Renal: ~90% as glucuronide conjugates (diflunisal acyl glucuronide, diflunisal phenolic glucuronide); <5% unchanged. Biliary/fecal: minimal, <10%.
Primarily renal (biliary/fecal minor). Approximately 60-70% excreted in urine as glucuronide conjugates and unchanged drug; 5-10% in feces via bile.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug
Nonsteroidal Anti-inflammatory Drug
"Oxyphenbutazone may increase the neuroexcitatory activities of Trovafloxacin."